Immortal Hair
Would you like to react to this message? Create an account in a few clicks or log in to continue.

Search
 
 

Display results as :
 


Rechercher Advanced Search

Check Out Our Sponsors
Brought to you by
Hair Loss Forum
Navigation
 Portal
 Index
 Memberlist
 Profile
 FAQ
 Search
Latest topics
» zombie cells
Interesting case study about Lp(a) EmptyToday at 3:01 am by shaftless

» Sandalore - could it be a game changer?
Interesting case study about Lp(a) EmptyWed May 08, 2024 9:45 pm by MikeGore

» *The first scientific evidence in 2021 that viruses do not exist*
Interesting case study about Lp(a) EmptyTue May 07, 2024 4:18 am by CausticSymmetry

» China is at it again
Interesting case study about Lp(a) EmptyTue May 07, 2024 4:07 am by CausticSymmetry

» Ways to increase adult stem cells
Interesting case study about Lp(a) EmptyMon May 06, 2024 5:40 pm by el_llama

» pentadecanoic acid
Interesting case study about Lp(a) EmptySun May 05, 2024 10:56 am by CausticSymmetry

» Exosome Theory and Herpes
Interesting case study about Lp(a) EmptyFri May 03, 2024 3:25 am by CausticSymmetry

» Road to recovery - my own log of everything I'm currently trying for HL
Interesting case study about Lp(a) EmptyTue Apr 30, 2024 1:55 pm by JtheDreamer

» Medical Coder During C0NV!D
Interesting case study about Lp(a) EmptySat Apr 27, 2024 4:00 pm by CausticSymmetry

Navigation
 Portal
 Index
 Memberlist
 Profile
 FAQ
 Search

Interesting case study about Lp(a)

3 posters

Go down

Interesting case study about Lp(a) Empty Interesting case study about Lp(a)

Post  mphatesmpb Fri Apr 01, 2011 7:25 pm

image
Cholesterol Not a Complete Picture of Heart Disease Risk
By William Davis, MD, FACC

Life Extension is pleased to introduce Case History, a new column in which medical practitioners present real-life case studies of patients overcoming medical problems through the use of complementary treatments, including supplements and other natural remedies.

Dr. William Davis writes our inaugural column. Dr. Davis is an author, lecturer, and cardiologist who specializes in coronary disease regression and strategies to improve human performance. He practices in Milwaukee, WI. He can be contacted at trackyourplaque.com.

Lisa, a 43-year-old wife and mother of two teenage children, works as a technologist at a local hospital. She became increasingly concerned about her medical future after her father died without warning of a fatal heart attack at age 59. More recently, her brother, who at 45 is just two years older than Lisa, had his second heart attack. Fortunately, he survived and had a stent placed in one of his coronary arteries.

Lisa has an upbeat, pleasant personality. She is a non-smoker and is thin and physically active. She has followed a low-fat diet for a number of years. At the start of the program, her LDL (“bad”) cholesterol was 68 and her HDL (“good”) cholesterol was a healthy 74—all without any treatment. Her primary-care physician had advised Lisa that on the basis of her lipid values, she is not at risk for a coronary “event” and has somehow escaped the genetic patterns of her father and brother.

Lisa expressed a desire to avoid a heart attack or having to undergo any kind of heart procedure. She therefore had a heart scan (performed using an ultra-fast electron beam tomography, or EBT, scanner) to obtain a calcium score, an indirect measure of silent coronary plaque. Her score of 447 placed her in the worst 1% (99th percentile) of all women her age. In fact, Lisa had the highest score I have ever seen in a woman under 50 years of age. After recovering from the initial shock of discovering her exceptionally high coronary calcium score, she sought to better understand why she had such extensive coronary plaque despite “normal” lipids.

Through a more thorough lipoprotein analysis, Lisa was found to have an abnormally high lipoprotein (a), or Lp(a), level of 85 mg/dl. This, in fact, was the only abnormality in her otherwise perfect profile. (Lisa’s testing included lipoprotein analysis performed via nuclear magnetic resonance (NMR) spectroscopy to assess LDL particle number and particle size, HDL sub-fractions, VLDL and its sub-fractions, C-reactive protein, and homocysteine.)

Lisa’s treatment program therefore focused on lowering her Lp(a) using:

Niacin—3000 mg of oral Niaspan® (Niaspan® is the prescription form of vitamin B3/niacin) once a day along with 325 mg of aspirin to limit flushing.

L-carnitine—1000 mg twice a day; lowers Lp(a) 7-8%

Flaxseed—2 tbsp per day, ground; lowers Lp(a) 7%

Raw almonds—1/4-1/2 cup per day; lowers Lp(a) 7-10%

Fish oil capsules—4000 mg/day (to yield 1200 mg of omega-3 fatty acids); lowers Lp(a) up to 14%.


Lisa also was advised to add to her diet 6000 mg of l-arginine taken twice a day on an empty stomach. Considering her excellent LDL and HDL scores (and their accompanying sub-fractions), Lisa was advised to continue the low-fat, high-fiber, unprocessed-food diet program that she had begun on her own.

After a year on this program, Lisa’s Lp(a) was a very safe 28 mg/dl. Her HDL was 93 and her LDL was 47—notable improvements over her already excellent starting values. A heart scan was repeated to re-assess how much her plaque had grown, and the resulting coronary calcium score was essentially unchanged. (Untreated, the score increases by an average of 30% per year.) Our hope is to achieve a reduction in score in Lisa’s second year of participation in order to essentially “turn off” Lisa’s coronary plaque.

Discussion
Lisa’s high heart scan score indicates that her coronary plaque was well established and extensive. Lisa’s risk for heart attack over the next 10 years was a significant 45%, with virtually a 100% likelihood of heart attack, bypass surgery, or stents over a longer timeline.1 Lipids provide a measure of potential coronary disease, but only in a statistical sense; they are not a measure of coronary plaque itself. Lisa’s case is an excellent example of how conventional lipid values can fail to identify risk for coronary disease even when plaque is present to an extreme degree. (By the way, Lisa’s stress test was normal as well. Had we relied on a stress test to determine whether Lisa was at risk, we would have completely “missed the boat.”)

High Lp(a) is an inherited abnormality that has implications for plaque growth, blood clotting, and abnormal artery constriction (“endothelial dysfunction”), and it is frustratingly unresponsive to many lifestyle modifications.2 Specific approaches are therefore required to treat it effectively. Because high Lp(a) can be very difficult to treat, the treatment program used in this case included both niacin and nutritional adjustments. The flaxseed, raw almonds, l-carnitine, and omega-3 fatty acids prescribed in Lisa’s case have been shown in clinical studies to provide a measurable benefit in reducing Lp(a).3-5 L-arginine, though it does not lower Lp(a), can be a powerful adjunct to facilitate plaque shrinkage, reduce plaque inflammation, and reverse the abnormal arterial constriction that is a particularly difficult problem when high Lp(a) is present.6

Lp(a) can manifest as an excessive constrictive behavior in coronary arteries that permits “spasm,” or a vise-like pinching shut of a segment of artery provoked by emotional upset, exposure to cold, or exercise. This leads to chest pain, or angina.7 Excessive arterial constriction also can manifest as high blood pressure, which can be especially troublesome in people afflicted with high Lp(a), who often require the use of three, four, or five anti-hypertensive medications to lower their blood pressure. L-arginine has blood-pressure-lowering effects that, in my experience, will often permit the subtraction of one or more anti-hypertensive medications when used consistently over a period of three to six months.

Omega-3 fatty acids (as fish oil) can lower Lp(a), particularly when triglycerides are greater than 150 mg/dl.8 Even in the absence of elevated triglycerides, however, the benefits of omega-3 fatty acids are so broad—a 30% reduction in coronary “events” and sudden death, a mild HDL-raising effect, and reduced fibrinogen (a blood-clotting protein that can lead to heart attack), not to mention the cancer-preventing effects9—that they are easily justified in a case like this.

Conclusions
High Lp(a) is a potent cause of heart disease that is not evident through standard cholesterol testing but can lead to heart attack in women as early as in their mid-50s and in men as early as in their late 40s. A combination of niacin and several nutritional supplements—especially flaxseed, raw almonds,l-carnitine, l-arginine, and omega-3 fatty acids—can help control this potent and often unrecognized cause of heart disease.

Editor’s note: Some people cannot tolerate high amounts of niacin because of the resulting “niacin flush” or excess stomach acidity. Those with liver disease should not take niacin.
mphatesmpb
mphatesmpb

Posts : 621
Join date : 2010-10-21

Back to top Go down

Interesting case study about Lp(a) Empty Re: Interesting case study about Lp(a)

Post  Mastery Sat Apr 02, 2011 12:26 am

Excellent piece.

Shows how outdated other stuff is.

M
Mastery
Mastery

Posts : 627
Join date : 2010-09-27

Back to top Go down

Interesting case study about Lp(a) Empty Re: Interesting case study about Lp(a)

Post  mphatesmpb Thu Jun 02, 2011 5:15 am


Lipoprotein(a)

Summary:

* Liberal fat intakesome saturated fats from eggs, meats (non-cured and processed), dairy; monounsaturated; fish oil
* Completely avoid hydrogenated, “trans,” fats
* Wheat and cornstarch reduction or elimination

Scientific Summary of the Lp(a) experience
(adapted from Unique Strategies for Lipoprotein(a) Reduction)

Low-carbohydrate diets may reduce Lp(a) modestly. A carefully conducted University of Connecticut study in 29 overweight men showed that a diet of 13% carbohydrate, 60% fat (no controlled proportions of saturated, polyunsaturated, etc.), 27% protein, without restriction in calories resulted in an average of 11% reduction in Lp(a). Interestingly, the average weight loss was 16.5 lbs over the three-month period (Wood RJ et al, 2006).

On the other hand, fat restriction (low-fat, high-carbohydrate diet) raises Lp(a), as demonstrated by another study in 37 healthy women in which Lp(a) increased 7–9% by reducing total fat intake from 36% of calories to 31%, achieved by reducing saturated fat (Silaste M et al 2004). Another study in 140 men showed a similar effect (Shin MJ et al 2007).

With regards to fat composition of the diet, omega-3 fatty acids from fish oil capsules and eating fish (see above) have the potential for both reducing Lp(a) levels, as well as suppressing production of the most undesirable small apo(a) portion of the Lp(a) molecule. Saturated fats also reduce Lp(a). Saturated fat effects show great variation among different individuals, ranging from 5% to 30% lower Lp(a) with diet unrestricted in saturated fat. Interestingly, the stearic acid component of saturated fats stands out as the factor that raises Lp(a), unlike other saturated fatty acids palmitic, lauric, and myristic fatty acids, which do not (Müller H et al 2003; Sanders TAB et al 1997). Stearic acid is especially plentiful in the saturated fat from chocolate (43% of total fat) and red meats (14%). (There are no studies specifically examining the effects of dark chocolate or cocoa on Lp(a).) Nonetheless, the net effect of saturated fat is Lp(a) reduction.

Trans fatty acids (hydrogenated fats) raise Lp(a), generally around 5%, though some people show much greater increases (Clevidence BA et al 1997; Mensink RP et al 1992). Although monounsaturated fats (e.g, canola, olive) may be desirable from an insulin-sensitizing standpoint, they may also raise Lp(a) by 10–12% (Vessby B et al 2002). From a fat composition viewpoint, a diet rich in omega-3 fatty acids and saturated fats, and low in hydrogenated trans-fats and perhaps monounsaturates, is therefore most beneficial for Lp(a) reduction.

Weight loss may result in modest reduction of Lp(a) in obese or overweight people. In one small French experience in 62 overweight people, participants with Lp(a) >20 mg/dl experienced 17.6% reduction in Lp(a) with weight loss of approximately 15 lbs over 6 weeks, achieved through calorie restriction (Kiortsis DN et al 2001). 



Soy protein

Soy protein, while exerting a modest LDL-reducing effect, may also increase Lp(a) 15-20%, while the dairy protein, casein, may reduce Lp(a) (Nilausen K 1999; Teede HJ et al 2001). However, these observations have not been consistent; one small study in females suggested no Lp(a) effect (Merz-Demlow BE et al 2000), another larger study in 130 participants receiving 30 grams soy protein also showed no effect (Tonstad S et al 2002).



Alcohol

Alcohol, i.e., ethanol provided by alcoholic beverages, reduces Lp(a) in a dose-dependent manner: the more you drink, the more Lp(a) is reduced, up to 57% reduction, an observation confirmed in a number of studies (Fontana P et al 1999; Välimeli M et al 1991; Marth E et al). Unlike the apo(a)-size effects of omega-3 fatty acids, alcohol did not exert any beneficial effect on apo(a) profile, despite the reduction in Lp(a), according to one very well-conducted study (Fontana P et al 1999). Conversely, withdrawal of alcohol from chronic users triggers a rebound of Lp(a), an effect also confirmed in several studies (Huang CM et al 1992). 

Although deeply-pigmented red wines are suspected to provide benefits over and above their alcohol content (presumably due to flavonoid content), no such specific relationship with Lp(a) has been identified.

Of course, there are other effects of alcohol to consider, including beneficial rises in HDL at low quantities (up to two servings a day), but increasingly adverse effects, including increased triglycerides and blood pressure (more than four drinks per day), with greater amounts.

Flaxseed and almonds

Ground flaxseed (2 tbsp/day) and raw almonds (1/4 cup/day) achieves Lp(a) reductions of approximately 7% (Jenkins DJ et al 2002). Both foods not only reduce Lp(a), but also reduce LDL and may partly counteract the small LDL particle size tendency through their blood sugar-reducing effect.
mphatesmpb
mphatesmpb

Posts : 621
Join date : 2010-10-21

Back to top Go down

Interesting case study about Lp(a) Empty Re: Interesting case study about Lp(a)

Post  j87x Thu Jun 02, 2011 5:59 am

I think this looks just as outdated as everything else, it mentions a low fat diet, doesn't mention carbs, etc. Would like hear someone who is more of an expert on the subject chime in though.
Meanwhile this thread is useful: https://immortalhair.forumotion.com/t3974-the-cholesterol-myth-that-is-harming-your-health-by-dr-mercola?highlight=cholesterol

j87x

Posts : 693
Join date : 2008-08-22

Back to top Go down

Interesting case study about Lp(a) Empty Re: Interesting case study about Lp(a)

Post  mphatesmpb Thu Jun 02, 2011 6:22 am

j87x,

This is an excerpt from the article:


Low-carbohydrate diets may reduce Lp(a) modestly. A carefully conducted University of Connecticut study in 29 overweight men showed that a diet of 13% carbohydrate, 60% fat (no controlled proportions of saturated, polyunsaturated, etc.), 27% protein, without restriction in calories resulted in an average of 11% reduction in Lp(a). Interestingly, the average weight loss was 16.5 lbs over the three-month period (Wood RJ et al, 2006).

On the other hand, fat restriction (low-fat, high-carbohydrate diet) raises Lp(a), as demonstrated by another study in 37 healthy women in which Lp(a) increased 7–9% by reducing total fat intake from 36% of calories to 31%, achieved by reducing saturated fat (Silaste M et al 2004). Another study in 140 men showed a similar effect (Shin MJ et al 2007).

It states that a high carbohydrate diet may increase Lp(a) levels, and that high fat diets (especially saturated fat) might decrease them.
mphatesmpb
mphatesmpb

Posts : 621
Join date : 2010-10-21

Back to top Go down

Interesting case study about Lp(a) Empty Re: Interesting case study about Lp(a)

Post  Sponsored content


Sponsored content


Back to top Go down

Back to top

- Similar topics

 
Permissions in this forum:
You cannot reply to topics in this forum